The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Interactions between cannabidiol and commonly used antiepileptic drugs
Open accessAbstract
Summary: Objective: To identify potential pharmacokinetic interactions between the pharmaceutical formulation of cannabidiol ( CBD ; Epidiolex) and the commonly used antiepileptic drugs ( AED s) through an open‐label safety study. Serum levels were monitored to identify interactions between CBD and AED s. Methods: In 39 adults and 42 children, CBD dose was started at 5 mg/kg/day and increased every 2 weeks by 5 mg/kg/day up to a maximum of 50 mg/kg/day. Serum AED levels were obtained at baseline prior to CBD initiation and at most study visits. AED doses were adjusted if it was determined that a clinical symptom or laboratory result was related to a potential interaction. The Mixed Procedure was used to determine if there was a significant change in the serum level of each of the 19 AED s with increasing CBD dose. AED s with interactions seen in initial analysis were plotted for mean change in serum level over time. Subanalyses were performed to determine if the frequency of sedation in participants was related to the mean serum N ‐desmethylclobazam level, and if aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were different in participants taking concomitant valproate. Results: Increases in topiramate, rufinamide, and N ‐desmethylclobazam and decrease in clobazam (all p < 0.01) serum levels were seen with increasing CBD dose. Increases in serum levels of zonisamide (p = 0.02) and eslicarbazepine (p = 0.04) with increasing CBD dose were seen in adults. Except for clobazam and desmethylclobazam, all noted mean level changes were within the accepted therapeutic range. Sedation was more frequent with higher N ‐desmethylclobazam levels in adults (p = 0.02), and AST / ALT levels were significantly higher in participants taking concomitant valproate (p < 0.01). Significance: Significantly changed serum levels of clobazam, rufinamide, topiramate, zonisamide, and eslicarbazepine were seen. Abnormal liver function test results were noted in participants taking concomitant valproate. This study emphasizes the importance of monitoring serum AED levels and LFT s during treatment with CBD .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., & Wright, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611618 · Cited by 1,711
Devinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras‐Aswad, D., Notcutt, W. G., et al. (2014) · Epilepsia · doi:10.1111/epi.12631 · Cited by 1,000
Marson, A. G., Al-Kharusi, A. M., Alwaidh, M., Appleton, R., Baker, G. A., Chadwick, D. W., Cramp, C., Cockerell, O. C., Cooper, P. N., Doughty, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60460-7 · Cited by 976
Marson, A. G., Al-Kharusi, A. M., Alwaidh, M., Appleton, R., Baker, G. A., Chadwick, D. W., Cramp, C., Cockerell, O. C., Cooper, P. N., Doughty, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60461-9 · Cited by 969
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00379-8 · Cited by 900
Molecular Targets of Cannabidiol in Neurological Disorders
Ibeas Bih, C., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 578
Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy
Geffrey, A. L., Pollack, S. F., Bruno, P. L., & Thiele, E. A. (2015) · Epilepsia · doi:10.1111/epi.13060 · Cited by 496
Antiepileptic drug interactions—Principles and clinical implications
I. Johannessen, S., & Johannessen Landmark, C. (2010) · Current Neuropharmacology · doi:10.2174/157015910792246254 · Cited by 343
Jiang, R., Yamaori, S., Takeda, S., Yamamoto, I., & Watanabe, K. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.05.018 · Cited by 322
Cannabinoids and Cytochrome P450 Interactions
Zendulka, O., Dovrtělová, G., Nosková, K., Turjap, M., Šulcová, A., Hanuš, L., & Juřica, J. (2016) · Current Drug Metabolism · doi:10.2174/1389200217666151210142051 · Cited by 291
Rosenberg, E. C., Tsien, R. W., Whalley, B. J., & Devinsky, O. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0375-5 · Cited by 276
Perucca, E., Cloyd, J. C., Critchley, D. J. P., & Fuseau, E. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01665.x · Cited by 260
Cannabinoids in the Treatment of Epilepsy
Friedman, D., & Devinsky, O. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1407304 · Cited by 241
Cannabidiol Is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19
Jiang, R., Yamaori, S., Okamoto, Y., Yamamoto, I., & Watanabe, K. (2013) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rg-129 · Cited by 199
Rosenberg, E. C., Patra, P. H., & Whalley, B. J. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.11.006 · Cited by 193
Consroe, P. F., & Wolkin, A. L. (1977) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30824-4 · Cited by 152
Cannabidiol, a Major Phytocannabinoid, As a Potent Atypical Inhibitor for CYP2D6
Yamaori, S., Okamoto, Y., Yamamoto, I., & Watanabe, K. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.041384 · Cited by 152
Cannabis, cannabidiol, and epilepsy — From receptors to clinical response
Szaflarski, J. P., & Bebin, E. M. (2014) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2014.08.135 · Cited by 152
Self-citationClinical Pharmacology of Topiramate: A Review
Garnett, W. R. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb02174.x · Cited by 148
The anticonvulsant activity of cannabidiol and cannabinol
Karler, R., Cely, W., & Turkanis, S. A. (1973) · Life Sciences · doi:10.1016/0024-3205(73)90141-0 · Cited by 131
Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents
Carlini, E. A., Leite, J. R., Tannhauser, M., & Berardi, A. C. (1973) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1973.tb10660.x · Cited by 125
Almeida, L., Falcão, A. C., Maia, J., Mazur, D., Gellert, M., & Soares-da-Silva, P. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005279364 · Cited by 102
de León, J., Spina, E., & Díaz, F. J. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31827ada88 · Cited by 95
CHESHER, G. B., & Jackson, D. M. (1974) · Psychopharmacology · doi:10.1007/bf00421539 · Cited by 84
Characterization of cannabidiol-mediated cytochrome P450 inactivation
Bornheim, L. M., Everhart, E. T., Li, J., & Correia, M. A. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90286-6 · Cited by 64
Lim, Y.-P., Ma, C.-Y., Liu, C., Lin, Y.-H., Hu, M.-L., Chen, J., Hung, D., Hsieh, W., & Huang, J.-D. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/242810 · Cited by 51
Pharmacokinetics of New Antiepileptic Drugs
Gram, L. (1996) · Epilepsia · doi:10.1111/j.1528-1157.1996.tb06034.x · Cited by 37
The Antiepileptic Potential of the Cannabinoids
Karler, R., & Turkanis, S. A. (1976) · Springer eBooks · doi:10.1007/978-1-4613-4286-1_28 · Cited by 28
Tolbert, D. S., Bekersky, I., Chu, H., & Ette, E. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.603 · Cited by 20
Therapeutic Drug Monitoring of Classical and Newer Anticonvulsants
Luke, M. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-385467-4.00012-9 · Cited by 6
Cited by
Cannabinoids and the expanded endocannabinoid system in neurological disorders
Cristino, L., Bisogno, T., & Di Marzo, V. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0284-z · Cited by 970
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Millar, S. A., Stone, N. L., Yates, A. S., & O'Sullivan, S. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01365 · Cited by 560
Taylor, L., Gidal, B., Blakey, G., Tayo, B., & Morrison, G. (2018) · CNS Drugs · doi:10.1007/s40263-018-0578-5 · Cited by 471
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
Devinsky, O., Patel, A. D., Thiele, E. A., Wong, M. H., Appleton, R., Harden, C. L., Greenwood, S., Morrison, G., Sommerville, K., On behalf of the GWPCARE1 Part A Study Group, et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005254 · Cited by 458
Brown, J., & Winterstein, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070989 · Cited by 295
Metadata
- Authors
- Gaston, T. E., Bebin, E. M., Cutter, G. R., Liu, Y., Szaflarski, J. P., & Program, T. U. C.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2017-08-06
- Volume
- 58
- Issue
- 9
- Pages
- 1586-1592
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2744115661
- Cited by
- 349
- References
- 30
- FWCI
- 26.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.